MedTrace Logo

Analgesic Treatment Mediated by Arcoxia (0663-093)

NCT00380523 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2022-02-16

No results posted yet for this study

Summary

Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Conditions

Interventions

DRUG

MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380523 on ClinicalTrials.gov